Meranda Parascandola - DSI InPharmatics

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

Why PDUFA VII User Fees Are on the Rise in 2025

The Prescription Drug User Fee Act (PDUFA) has been a cornerstone of the U.S. Food and Drug Administration’s (FDA) drug approval process since its inception in 1992. With the implementation of PDUFA VII (2023-2027), user fees for FY 2025 have been published, reflecting a notable increase that will impact pharmaceutical […]

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

How to Exercise FDA Inspection Readiness

FDA inspections are a critical aspect of regulatory compliance for pharmaceutical, biotech, and medical device companies. A well-prepared organization can navigate inspections smoothly, avoid compliance violations, and maintain operational efficiency. This article outlines the key steps companies should take to ensure FDA inspection readiness. Understanding FDA Inspections The U.S. Food […]

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

BLA vs. NDA: What’s the Difference?

Navigating the regulatory pathways for drug approvals in the U.S. can be complex, especially when determining whether a Biologics License Application (BLA) or a New Drug Application (NDA) is the appropriate route. While both serve as formal requests for market approval from the FDA, they apply to different types of […]

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

What to Expect from CBER Breakthrough Approvals in 2025

The Center for Biologics Evaluation and Research (CBER) plays a critical role in overseeing the approval of innovative biologic products, including gene therapies, cell-based treatments, and vaccines. While CBER and the Center for Drug Evaluation and Research (CDER) jointly evaluate breakthrough therapy designations, CBER focuses on advanced biologics, ensuring timely […]

April 18, 2025

Published by Meranda Parascandola at April 18, 2025

What Are the Five Pillars of Drug Development Consulting Services?

Discover the five pillars of drug development consulting: regulatory compliance, clinical trials, preclinical research, CMC, and market access.

April 25, 2025

Published by Meranda Parascandola at April 25, 2025

When Should You Consider Drug Product Development Services?

Navigating the complexities of drug development demands more than internal resources. From overcoming technical hurdles and avoiding costly or inappropriate development paths to meeting regulatory standards, every stage—discovery to market—presents unique challenges. At key moments, companies must recognize when external expertise isn't just helpful but crucial. Partnering with the right […]